Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEITHO-3 reduced-dose alteplase trial in intermediate-high-risk acute pulmonary embolism
NL-OMON60346Phase 3Active, not recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of tissue-plasminogen activator in pulmonary embolism (PE) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Primary composite efficacy endpoint. Started Oct 2024; status: active, not recruiting.
02
Drugs
tissue-plasminogen activator
03
Conditions
pulmonary embolism (PE)
Beyond the preview
Go deeper on NL-OMON60346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60346.